Last reviewed · How we verify

Placebo to Pembrolizumab

Merck Sharp & Dohme LLC · Phase 3 active Small molecule

Placebo to Pembrolizumab is a PD-1 inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma. Also known as: Normal Saline or Dextrose solution.

Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.

Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells. Used for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma.

At a glance

Generic namePlacebo to Pembrolizumab
Also known asNormal Saline or Dextrose solution
SponsorMerck Sharp & Dohme LLC
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Pembrolizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing interaction with its ligands (PD-L1 and PD-L2) on tumor cells and antigen-presenting cells. This blockade releases the 'brakes' on T-cell-mediated immunity, restoring anti-tumor immune responses. The drug is being evaluated in this Phase 3 trial as a comparison to placebo control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to Pembrolizumab

What is Placebo to Pembrolizumab?

Placebo to Pembrolizumab is a PD-1 inhibitor drug developed by Merck Sharp & Dohme LLC, indicated for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma.

How does Placebo to Pembrolizumab work?

Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.

What is Placebo to Pembrolizumab used for?

Placebo to Pembrolizumab is indicated for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma, Hodgkin lymphoma, Urothelial carcinoma.

Who makes Placebo to Pembrolizumab?

Placebo to Pembrolizumab is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is Placebo to Pembrolizumab also known as anything else?

Placebo to Pembrolizumab is also known as Normal Saline or Dextrose solution.

What drug class is Placebo to Pembrolizumab in?

Placebo to Pembrolizumab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Placebo to Pembrolizumab in?

Placebo to Pembrolizumab is in Phase 3.

What are the side effects of Placebo to Pembrolizumab?

Common side effects of Placebo to Pembrolizumab include Fatigue, Decreased appetite, Nausea, Diarrhea, Rash, Immune-mediated pneumonitis.

What does Placebo to Pembrolizumab target?

Placebo to Pembrolizumab targets PD-1 and is a PD-1 inhibitor.

Related